BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 1739355)

  • 1. A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients.
    Rolston KV; Berkey P; Bodey GP; Anaissie EJ; Khardori NM; Joshi JH; Keating MJ; Holmes FA; Cabanillas FF; Elting L
    Arch Intern Med; 1992 Feb; 152(2):283-91. PubMed ID: 1739355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicenter, randomized trial of ciprofloxacin plus azlocillin versus ceftazidime plus amikacin for empiric treatment of febrile neutropenic patients.
    Flaherty JP; Waitley D; Edlin B; George D; Arnow P; O'Keefe P; Weinstein RA
    Am J Med; 1989 Nov; 87(5A):278S-282S. PubMed ID: 2686429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of two antibiotic regimens (piperacillin plus amikacin versus ceftazidime plus amikacin) as empiric therapy for febrile neutropenic patients with cancer.
    Feliu J; Artal A; González Barón M; Berrocal A; Chacón I; García de Paredes ML; Espinosa E; Ordóñez A; Zamora P; Montero JM
    Antimicrob Agents Chemother; 1992 Dec; 36(12):2816-20. PubMed ID: 1482151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomised comparison of ceftazidime and imipenem as initial monotherapy for febrile episodes in neutropenic cancer patients.
    Aparicio J; Oltra A; Llorca C; Montalar J; Herranz C; Gómez-Codina J; Pastor M; Munárriz B
    Eur J Cancer; 1996 Sep; 32A(10):1739-43. PubMed ID: 8983283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monotherapy with piperacillin/tazobactam versus combination therapy with ceftazidime plus amikacin as an empiric therapy for fever in neutropenic cancer patients.
    Hess U; Böhme C; Rey K; Senn HJ
    Support Care Cancer; 1998 Jul; 6(4):402-9. PubMed ID: 9695210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meropenem monotherapy versus combination therapy with ceftazidime and amikacin for empirical treatment of febrile neutropenic patients.
    Behre G; Link H; Maschmeyer G; Meyer P; Paaz U; Wilhelm M; Hiddemann W
    Ann Hematol; 1998 Feb; 76(2):73-80. PubMed ID: 9540761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Imipenem/cilastatin versus ceftazidime-amikacin in the treatment of febrile neutropenic patients].
    Pérez C; Sirham M; Labarca J; Grebe G; Lira P; Oliva J; Duhalde M; Ocqueteau M; Acuña G
    Rev Med Chil; 1995 Mar; 123(3):312-20. PubMed ID: 8525170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective, controlled, randomized, non-blind, comparative study of the efficacy and safety of a once daily high dose of ceftriaxone plus ciprofloxacin versus thrice daily ceftazidime plus amikacin in empirical therapy for febrile neutropenic patients.
    Metallidis S; Kollaras P; Giannakakis T; Seitanidis B; Kordosis T; Nikolaidis J; Hatzitolios A; Nikolaidis P
    Eur J Intern Med; 2008 Dec; 19(8):619-24. PubMed ID: 19046729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cefepime/amikacin versus ceftazidime/amikacin as empirical therapy for febrile episodes in neutropenic patients: a comparative study. The French Cefepime Study Group.
    Cordonnier C; Herbrecht R; Pico JL; Gardembas M; Delmer A; Delain M; Moreau P; Ladeb S; Nalet V; Rollin C; Gres JJ
    Clin Infect Dis; 1997 Jan; 24(1):41-51. PubMed ID: 8994754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ceftazidime plus amikacin versus ceftazidime plus vancomycin as empiric therapy in febrile neutropenic children with cancer.
    Viscoli C; Moroni C; Boni L; Bruzzi P; Comelli A; Dini G; Fabbri A; Secondo V; Terragna A
    Rev Infect Dis; 1991; 13(3):397-404. PubMed ID: 1866542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of febrile episodes in neutropenic leukemic patients with the antibiotic combinations piperacillin or ceftazidime plus amikacin: results of a randomized study.
    Fenu S; Raccah R; Santilli S; Micozzi A; Girmena C; Martino P; Avvisati G
    Chemioterapia; 1988 Oct; 7(5):323-6. PubMed ID: 3066517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer.
    Cometta A; Zinner S; de Bock R; Calandra T; Gaya H; Klastersky J; Langenaeken J; Paesmans M; Viscoli C; Glauser MP
    Antimicrob Agents Chemother; 1995 Feb; 39(2):445-52. PubMed ID: 7726513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ceftazidime versus imipenem-cilastatin as initial monotherapy for febrile neutropenic patients.
    Liang R; Yung R; Chiu E; Chau PY; Chan TK; Lam WK; Todd D
    Antimicrob Agents Chemother; 1990 Jul; 34(7):1336-41. PubMed ID: 2201252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imipenem compared with ceftazidime plus vancomycin as initial therapy for fever in neutropenic children with cancer.
    Riikonen P
    Pediatr Infect Dis J; 1991 Dec; 10(12):918-23. PubMed ID: 1766707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Empirical therapy with ceftazidime combined with levofloxacin or once-daily amikacin for febrile neutropenia in patients with neoplasia: a prospective comparative study.
    Samonis G; Koutsounaki E; Karageorgopoulos DE; Mitsikostas P; Kalpadaki C; Bozionelou V; Bompolaki I; Sgouros J; Taktikou V; Falagas ME
    Eur J Clin Microbiol Infect Dis; 2012 Jul; 31(7):1389-98. PubMed ID: 22037822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of aztreonam plus vancomycin and imipenem plus vancomycin as initial therapy for febrile neutropenic cancer patients.
    Raad II; Whimbey EE; Rolston KV; Abi-Said D; Hachem RY; Pandya RG; Ghaddar HM; Karl CL; Bodey GP
    Cancer; 1996 Apr; 77(7):1386-94. PubMed ID: 8608520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of amikacin and ceftazidime as empiric treatment of febrile leukopenic patients affected by solid tumors.
    Gasparini G; Benedetti M; Fassio T; Canobbio L; Figoli F; Galligioni E; Talamini R; Toffoli G; Tumolo S
    Int J Clin Pharmacol Ther Toxicol; 1987 Feb; 25(2):113-20. PubMed ID: 3549581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-daily ceftriaxone plus amikacin versus thrice-daily ceftazidime plus amikacin as empirical treatment of febrile neutropenia in children with cancer.
    Ariffin H; Arasu A; Mahfuzah M; Ariffin WA; Chan LL; Lin HP
    J Paediatr Child Health; 2001 Feb; 37(1):38-43. PubMed ID: 11168867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of febrile neutropenic patients with cancer who require hospitalization: a prospective randomized study comparing imipenem and cefepime.
    Raad II; Escalante C; Hachem RY; Hanna HA; Husni R; Afif C; Boktour MR; Whimbey EE; Kontoyiannis D; Jacobson K; Kantarjian H; Levett LM; Rolston KV
    Cancer; 2003 Sep; 98(5):1039-47. PubMed ID: 12942573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinafloxacin monotherapy (CI-960) versus ceftazidime plus amikacin for empirical treatment of febrile neutropenic cancer patients.
    Glauser MP; Brennscheidt U; Cornely O; Grigg A; Figuera A; Keyserling C; Trostmann U; Welling L; Tack K
    Clin Microbiol Infect; 2002 Jan; 8(1):14-25. PubMed ID: 11906496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.